Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
LITESPARK-024
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
- NCT05468697 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Standard
We haven't built an HCP commentary report on LITESPARK-024 (belzutifan plus palbociclib in advanced renal cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LITESPARK-024 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 | |
| YouTube | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- Belzutifan; Palbociclib
- Arms
- Beltuzifan 120 mg + Palbociclib 75 mg · Experimental
- Beltuzifan 120 mg + Palbociclib 100 mg · Experimental
- Beltuzifan 120 mg + Palbociclib 125 mg · Experimental
- Enrollment
- 60 (estimated)
- Primary outcomes
- Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT)
- Number of Participants Who Experience at Least One Adverse Event (AE)
- Number of Participants Who Discontinue Study Treatment Due to an AE
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Aug 10, 2022
- Primary completion
- Dec 22, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05468697 · updated Oct 27, 2026
Publications
linked from the registry- Meiman D, Skaar TC, Shugg T, Quinney SK. Physiologically Based Pharmacokinetic Model to Assess the Drug-Drug-Gene Interaction Potential of Belzutifan in Combination With Cyclin-Dependent Kinase 4/6 Inhibitors. JCO Precis Oncol. 2025 Jul;9:e2500153. doi: 10.1200/PO-25-00153. Epub 2025 Jul 25. PubMed 40712111